FRIDAY, 4 OCTOBER 2024

Note: All times listed are in Central European Summer Time (CEST)

9:00 AM – 10:10 AM: PSC Clinical Trial Considerations: Drug Product, Cell Delivery, Trial Design, & Clinical Endpoints I
Room: Queen’s Hall

9:00 AM – 9:15 AM | Opening Remarks
Joachim Fruebis, Novo Nordisk, Denmark

9:15 AM - 9:45 AM
Nicholas Boulis, The Emory University, USA
PRACTICAL CONSIDERATIONS IN SPINAL CORD STEM CELL TRANSPLANTATION

9:45 AM - 9:55 AM | Innovation Showcase: PeptiGrowth Inc.
Robert Brownlee, PeptiGrowth Inc., UK
INNOVATIVE SYNTHETIC PEPTIDE-BASED GROWTH FACTOR: OVERCOMING CHALLENGES IN STEM CELL MEDICINE PRODUCTION

9:55 AM - 10:10 AM
Andras Nagy, Lunenfeld Tanenbaum Research Institute, Sinai Health, Canada
CELL THERAPY SAFETY IS A MULTIFACETED TARGET

10:10 AM – 10:40 AM: Refreshment Break
Room: Foyer

10:40 AM – 12:00 PM: PSC Clinical Trial Considerations: Drug Product, Cell Delivery, Trial Design, & Clinical Endpoints II
Room: Queen’s Hall

10:40 AM – 11:10AM
Clive Svendsen, Cedars-Sinai Medical Center, USA
UNIQUE ASPECTS OF CELL THERAPY FOR NEUROLOGICAL DISEASE

11:10 AM - 12:00 PM | PSC-Derived Drug Product, Cell Delivery, and Clinical Trials Discussion Panel Discussion

Moderator:

Joachim Fruebis, Novo Nordisk, Denmark

Panelists:

Nicholas Boulis, The Emory University, USA

Masayo Takahashi, Vision Care, Japan

Cory Nicholas, Neurona Therapeutics, USA

Clive Svendsen, Cedars-Sinai Medical Center, USA

Andres Bratt-Leal, Aspen Neuroscience, USA

Andras Nagy, Lunenfeld Tanenbaum Research Institute, Sinai Health, Canada

12:00 PM – 1:15 PM: Lunch
Room: Foyer

1:15 PM – 2:45 PM: Immunosuppression & Immune Evasion
Room: Queen’s Hall

1:15 PM - 1:45 PM
Tobias Deuse, University of California San Francisco, USA
ALLOGENEIC HYPOIMMUNE CELL THERAPEUTICS AS UNIVERSAL MEDICINES

1:45 PM - 2:00 PM
Maria Cristina Nostro, McEwen Stem Cell Institute, Canada
ISLET-LIKE CELLS GENERATED FROM HLA-E EXPRESSING HUMAN EMBRYONIC STEM CELLS LACKING B2M AND RFXANK AVOID ALLOREJECTION IN VITRO AND IN VIVO

2:00 PM - 2:15 PM
Mathias Brunet Manquat, Sorbonne Université, France
ESTABLISHED NEW IMMUNODEFICIENT LARGE ANIMAL MODEL FOR RECEIVING HUMAN INDUCED PLURIPOTENT STEM CELL-DERIVED HEMATOPOIETIC GRAFTS

2:15 PM - 2:45 PM
Chad Cowan, Century Therapeutics, USA
UNIVERSAL CLOAKING OF ALLOGENEIC T CELL THERAPIES AGAINST NATURAL KILLER CELLS VIA CD300A AGONISM

2:45 PM – 3:15 PM: Refreshment Break
Room: Foyer

3:15 PM – 5:00 PM: Next Generation Technologies & Platforms
Room: Queen’s Hall

3:15 PM - 3:45 PM
Alice Chen, Trestle Biotherapeutics, USA
BIOENGINEERING HUMAN KIDNEYS TO TREAT KIDNEY FAILURE

3:45 PM - 3:55 PM | Innovation Showcase: CCRM
Janet Rothberg, CCRM, Canada
MOVING IPSC BASED CGT INTO A GMP SETTING

3:55 PM - 4:10 PM
Ricardo Baptista, SmartCella, Sweden
DEVELOPING MANUFACTURING PLATFORMS AND TARGETED PRECISE DELIVERY OF ADVANCED THERAPIES

4:10 PM - 4:25 PM
Elisa Pedone, CellVoyant, UK
FateView™: NON-INVASIVE LONGITUDINAL AND FUNCTIONAL CHARACTERISATION OF STEM CELLS POWERED BY AI

4:25 PM - 4:55 PM
Peter Zandstra, UBC & Notch Therapeutics, Canada
PRODUCTION OF ALLOGENEIC CAR-T CELLS AND CD4+ T CELLS FROM IPSCS TO ADVANCE IMMUNOTHERAPIES

4:55 PM - 5:00 PM | Closing Remarks
Kapil Bharti, NEI/NIH, USA

<
View Thursday, 3 October 2024 Agenda